Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Explore optimal timing of arsenic trioxide plus compound Huangdai tablets in polycythemia vera
ChiCTR2000041018Phase 4Recruiting
- Sponsor
- Southern Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of arsenic trioxide and Compound Huangdai Tablet in polycythemia vera (PV) (4 arms), sponsored by Southern Hospital. Primary endpoints: PML, RBC count and 2 more. Started Jan 2021; status: recruiting.
02
Drugs
arsenic trioxideCompound Huangdai Tablet
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on ChiCTR2000041018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041018.